Էջ 1 սկսած 33 արդյունքներ
BACKGROUND OF THE INVNON
1. Field of the Invention
The present invention is directed to aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds. In particular, this invention is directed to aryl-link-aryl thiazohdine-ione, and aryl-link-aryl oxazolidine-dione compounds which
FIELD OF THE INVENTION
The invention relates to new therapeutic techniques involving eslicarbazepine acetate or eslicarbazepine.
BACKGROUND OF THE INVENTION
An epileptic seizure is defined as a clinical event associated with a transient, hypersynchronous neuronal discharge. The seizure represents
FIELD OF THE INVENTION
The present invention relates to novel substituted morpholine and thiomorpholine derivatives being openers of the KCNQ family potassium ion channels. The compounds are useful in the treatment of disorders and diseases being responsive to opening of the KCNQ family potassium
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates in general to the field of transdermal and dermal drug delivery by using formulations of said compositions including chemical penetrants molecules, polar solvents, cream base, antioxidants and therapeutic
FIELD OF INVENTION
The invention relates to piperidine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists useful in the treatment of diseases and disorders responsive to antagonism of NMDA receptors.
BACKGROUND OF THE INVENTION
Many of the physiological and pathophysiological effects of the
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1838/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050917 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1840/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050924 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to novel acyl-urea containing compounds, and to uses of acyl-urea containing compounds in a variety of therapeutic applications, including, for example, neurological diseases and disorders such as
FIELD
The present invention belongs to pharmaceutical field, and in particular, relates to a novel KCNQ potassium channel agonist, the preparation therefor and the use of the KCNQ potassium channel agonist or the pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising
TECHNICAL FIELD
The present invention belongs to pharmaceutical field, and in particular, relates to a novel KCNQ potassium channel agonist, the preparation therefor and the use of the KCNQ potassium channel agonist or the pharmaceutically acceptable salt thereof or a pharmaceutical composition
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1834/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050909 filed on 3 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase of International Application No. PCT/US2014/027450 filed on Mar. 14, 2014, which claims the benefit of U.S. Provisional Application No. 61/785,478 filed on Mar. 14, 2013, each of which are incorporated herein by reference
FIELD OF THE INVENTION
The present invention relates to bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, including derivatives, positional isomers, and prodrugs thereof, compositions comprising the same and methods of making and using the same. The present invention also relates
PRIORITY
This application is a national phase filing of the Patent Cooperation Treaty (PCT) application # PCT/IB2013/050740 titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY" filed on Jan. 29, 2013. Published with WIPO Publication # WO/2013/167986 which further claims priority to patent
BACKGROUND OF THE INVENTION
Lennox-Gastaut Syndrome (LGS) is a severe pediatric epilepsy disorder associated with various types of seizures and cognitive dysfunction that persist into adulthood. As a result, LGS patients suffer from varying degrees of learning disabilities, psychiatric disorders,